NEWS
View news from our Featured Companies.
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis
NR improves muscle mitochondrial biogenesis, satellite cell differentiation and gut microbiota composition in first-ever five-month-long study in monozygotic twin pairs LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy...
Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants
ROCKVILLE, Md., Jan. 12, 2023 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side...
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)
Globally acclaimed authority on aging to further research on the potential benefits of nicotinamide riboside (NR) and age-related conditions. LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has...
Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications
ROCKVILLE, Md., Jan. 10, 2023 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the...
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT® as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR® for ADHD Patients
Aytu RxConnect Providing Access Relief to Patients Amid Ongoing Generic Adderall® Supply DisruptionENGLEWOOD, CO / January 10, 2023 / Millions of ADHD patients in the United States rely on FDA approved treatments to control their ADHD symptoms and many of them...
ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022
PORTLAND, Maine, Jan. 09, 2023 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website
- Kiora is advancing a pipeline of therapeutics for rare and underserved ophthalmic diseases - - Anticipates reporting results in 1H 2023 from two clinical studies, one in patients with Retinitis Pigmentosa and another in patients with persistent corneal epithelial...
Aytu BioPharma Announces 1-for-20 Reverse Stock Split
ENGLEWOOD, CO / January 5, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced a...
INVO Bioscience Enters Distribution Agreement for Taiwan
SARASOTA, Fla., Jan. 5, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC")...
ChromaDex Named Brianna Gerber Chief Financial Officer
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financial Officer, effective January 1, 2023. Gerber served as Senior Vice President, Finance /...
Reviva Pharmaceuticals Announces Letter to Shareholders
CUPERTINO, Calif., Jan. 04, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery
D-PLEX100 Achieved in Phase 2 Trial Significant Reduction in SSIs in Patients with Multiple Preoperative Risk Factors Versus Standard of Care Results Consistent with SHIELD I Phase 3 Post-hoc Analysis Demonstrating Significant Primary Endpoint Reduction in Patients...
Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023
Encinitas, California--(January 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced enrollment has been completed in its clinical study evaluating KIO-201 in patients with Persistent Corneal Epithelial Defects ("PCED"), a...
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers
Results from this study on healthy subjects support previous research demonstrating that NR supplementation may impact neurodegenerative biomarkers commonly associated with aging LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to...
SenesTech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHOENIX, Dec. 20, 2022 -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today reported the grant...
LiqTech and Ecolotron Wastewater Solutions Enter Cooperation Agreement on a Combined Solution for Phosphoric Acid Purification
BALLERUP, Denmark, Dec. 20, 2022 -- LiqTech International, Inc. (NASDAQ: LIQT), a clean technology company that manufactures and markets highly specialized filtration products and systems, has entered a cooperation agreement with USA-based Ecolotron Wastewater...
Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine
- Topline data for pivotal Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia expected in mid-2023 - Brilaroxazine is a serotonin/dopamine modulator with a differentiated pharmacological and safety profile CUPERTINO, Calif., Dec. 15, 2022 -- Reviva...
Precision Optics Announces Receipt of $2.6 Million Follow-On Production Order from Large Defense Company
GARDNER, Mass., Dec. 14, 2022 -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the receipt of a follow-on production order totaling...
Precision Optics to Ring Nasdaq Opening Bell on Wednesday, December 14, 2022
GARDNER, Mass., Dec. 13, 2022 -- Precision Optics Corporation, Inc. (Nasdaq: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced that Chief Executive Officer Joe Forkey and other Precision...
Zoomd Technologies Announces Results of Annual and Special Meeting of Shareholders, Re-Electing All Members of the Board of Directors
VANCOUVER, BC, Dec. 13, 2022 /CNW/ -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly-owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the online advertising management platform, announced today the results of its annual and...
PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
Meeting Scheduled for January 2023 PolyPid Recently Provided FDA with Currently Available Data from Completed SHIELD I Phase 3 Study in Advance of Meeting PETACH TIKVA, Israel, Dec. 12, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage...
PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification
PETACH TIKVA, Israel, Dec. 09, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced it has received a written notice (the "Notice") from Nasdaq Stock Market LLC ("Nasdaq")...
Precision Optics Announces New Product Development Order for Single Use Urology Program
GARDNER, Mass., Dec. 8, 2022 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the receipt of an initial product development order for a...
Zoomd Technologies Announces Appointment of Ido Almany as CEO
VANCOUVER, British Columbia, Dec. 8, 2022 /CNW/ -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly-owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the marketing technology (MarTech) user-acquisition and engagement platform, is...
Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications
ROCKVILLE, Md., Dec. 6, 2022 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the...